ArticleESMO open2022

Erratum to 'Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody Gatipotuzumab with the anti-EGFR Tomuzotuximab in patients with refractory solid tumors': [ESMO Open Volume 7, Issue 2, April 2022, 100447].

S Ochsenreither et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.